Neose Technologies, Inc. (NTEC) Announces Closing of Asset Sales to Novo Nordisk A/S (NVO) and BioGeneriX AG; First Step in Plan of Liquidation
1/28/2009 6:54:55 AM
More...
|
Neose Technologies, Inc. (NTEC) to Sell its Assets to Novo Nordisk A/S (NVO) and BioGeneriX AG for $43 Million
9/18/2008 7:07:03 AM
More...
|
Neose Technologies, Inc. (NTEC) Announces GlycoPEG-GCSF Abstract Accepted for Poster Presentation at IXth World Conference on Clinical Pharmacology and Therapeutics
7/28/2008 10:19:36 AM
More...
|
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Initiate Phase 2 Trial for GlycoPEG-GCSF
6/23/2008 10:35:53 AM
More...
|
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Announce Positive Data from Two Phase I Studies of GlycoPEG-GCSF
11/7/2007 10:47:11 AM
More...
|
BioGeneriX AG and Neose Technologies, Inc. (NTEC) to Host Conference Call to Present GlycoPEG-GCSF Phase I Data
11/1/2007 12:10:12 PM
More...
|
The Day In Review: BioSimilar Drug Enters Trial
3/21/2007 4:53:46 PM
More...
|
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Announce Initiation of 2nd Phase I Clinical Trial of GlycoPEG-GCSF; Interim Results From 1st Phase I Trial Show Dose-Dependent Response
3/21/2007 12:37:11 PM
More...
|
Neose Technologies, Inc. (NTEC) Announces BioGeneriX AG's Initiation Of Phase I Trial Of GlycoPEG-GCSF
11/9/2006 11:29:11 AM
More...
|
Neose Technologies, Inc. (NTEC) And BioGeneriX AG Announce Second Agreement For A GlycoPEGylated Next-Generation Protein; Milestone Payments Worth Up To $61.5 Million
10/19/2005 5:12:35 PM
More...
|
|